Niacinamide, a B Vitamin, may be of value to women with genetic risk of Breast Cancer and Ovarian Cancer.
Why are some women more prone to developing breast cancer and ovarian
cancer? This is a complex question. Every person and every cancer
constitute a unique and complex set of contributing factors.
One factor, related to genetics, is the inability to repair
damaged DNA(damaged genetic material inside the cell) effectively.
Damaged DNA, like damaged software, will send out incorrect operating
instructions to the cells in our body. This can lead to uncontrolled
growth and the development of cancerous tumor cells.
For those patients with genetics that lead to inefficient and
poor DNA repair who are therefore at high risk for aggressive cancers
there is a new class of drugs called "PARP inhibitors” undergoing
research and approval. While waiting for PARP inhibitor drugs to
finally be approved and available studies have demonstrated that the B
vitamin Niacinamidealso acts as a PARP inhibitor in doses that yield a
pharmacologic effect. Studies used 1.5 grams (1500 mg) three times
daily. PARP inhibition allows damaged DNA in the cell to be repaired.
Cells with damaged DNA are prone to develop into malignant cancerous
Women who are positive for the BRCA1 gene are known to have poor DNA
repair. These women may benefit from PARP inhibitors. BRCA1 is
associated with aggressive and often lethal breast cancer as well as
Recently another gene associated with poor DNA repair has been
identified.This gene, RAD51D,is associated with increased risk for
ovarian cancer. PARP Inhibitor drugs as well as Niacinamide may also be
of value to these women.
Here is an excerpt from article that appeared in Reuters Mon, Aug 8
2011By Kate Kelland LONDON (Reuters) – Women who carry a faulty copy of
a gene called RAS51D have an almost one in 11 chance of developing
ovarian cancer,scientists said on Sunday in a finding they called the
most significant ovarian cancer gene discovery for more than 10 years.
Tests to identify those at highest risk are expected to be available
within a few years, according to Cancer Research UK, and may lead some
women to decide to have their ovaries removed in order to beat the
The finding should also speed the search for new drugs.
Laboratory experiments already suggest that cells with faulty RAD51D
are sensitive to PARP inhibitors – a new class of drugs designed to
target cancers caused by faults in two known breast and ovarian
cancer genes, BRCA1and BRCA2.
For the latest study, researchers from Britain’s Institute of Cancer
Research compared the DNA of women from 911 families with ovarian and
breast cancer to DNA from a control group of more than 10,000 people
from the general population.
"Women with a fault in the RAD51D gene have a one in 11 chance of
developing ovarian cancer,” said Nazneen Rahman of the Institute of
Cancer Research and The Royal Marsden in London, who led the study and
published its findings in the journal Nature Genetics.
Ovarian cancer can remain hidden for a long time and thus is often not discovered until it is advanced.
An estimated 230,000 women worldwide are diagnosed with ovarian
cancer each year. Most are not diagnosed before the cancer has spread,
and up to 70 percent of them die within five years.
Speaking to Reuters in a telephone interview she said the
identification of RAD51D pointed to PARP inhibitors as a new class of
drugs that might offer fresh hope. Initial tests in the laboratory found
that cells with faulty RAD51D were highly sensitive to this class of
"PARP inhibitors work because they were designed to target DNA repair
pathways,” she said. "They haven’t been used in patients in that
context yet but we would predict they would behave in the same way.”
SOURCE: bit.ly/rdeooV Nature Genetics, online August 7, 2011.© Thomson Reuters 2011. All rights reserved.
*Niacinamide Monograph Alternative Medicine Review December 2002
Always consult your physician regarding any nutritional program.
These statements have not been approved by the FDA and do not constitute
medical advice or treatment which is between you and your physician.